General contact

Head Office
Novartis International AG
CH-4002 Basel

+41 61 324 11 11
+41 61 324 80 01
Monday - Friday,
8:30 - 17:00, GMT+1
(Central European Time)


Novartis International AG
Investor Relations
P.O. Box
CH-4002 Basel

+41 61 324 79 44


Global Oncology Media Relations
Denise Brashear
Novartis Oncology Global Public Relations

+1 862 778 7336

Novartis Media Relations
Eric Althoff
Basel, Switzerland

+41 61 324 7999

pane 4 content

This site is not intended for U.S. residents.


Glivec (imatinib), which is known as "Gleevec" in the United States, is a cancer treatment indicated for:

  • Adult and pediatric patients with newly diagnosed Philadelphia chromosome (bcr–abl) positive (Ph+) Chronic Myeloid Leukemia for whom bone marrow transplantation is not considered as the first line of treatment.
  • Adult and pediatric patients with Ph+ Chronic Myeloid Leukemia in chronic phase after failure of interferon-alfa therapy, or in accelerated phase or blast crisis.
  • Adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy.
  • Adult patients with relapsed or refractory Ph+ ALL as monotherapy.
  • Adult patients with myelodysplastic syndrome/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements.
  • Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRa rearrangement.

Glivec is also indicated for:

  • Adult patients with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
  • Adjuvant treatment of adult patients who are at significant risk of relapse following resection of KIT(CD 117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.
  • Adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

To contact us in your country of residence, please click here